Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Glaxo Wellcome |
---|---|
Information provided by: | NIH AIDS Clinical Trials Information Service |
ClinicalTrials.gov Identifier: | NCT00002000 |
To evaluate the safety and efficacy of oral valacyclovir hydrochloride (256U87) vs. acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients (CD4 greater than or equal to 100).
Condition | Intervention |
---|---|
Herpes Simplex HIV Infections |
Drug: Valacyclovir hydrochloride Drug: Acyclovir |
Study Type: | Interventional |
Study Design: | Treatment, Safety Study |
Official Title: | A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients |
Ages Eligible for Study: | 13 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have the following:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Patients with the following are excluded:
Prior Medication:
Excluded:
Study ID Numbers: | 104A, 08 |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00002000 |
Health Authority: | United States: Food and Drug Administration |
Acyclovir Acquired Immunodeficiency Syndrome AIDS-Related Complex |
Antiviral Agents Anus Diseases Herpes Genitalis |
Herpes Simplex Sexually Transmitted Diseases, Viral Skin Diseases Herpes Genitalis Acquired Immunodeficiency Syndrome AIDS-Related Complex Immunologic Deficiency Syndromes Recurrence Herpesviridae Infections |
Valacyclovir Virus Diseases Skin Diseases, Infectious Acyclovir HIV Infections Sexually Transmitted Diseases DNA Virus Infections Retroviridae Infections |
Skin Diseases, Viral Anti-Infective Agents Communicable Diseases RNA Virus Infections Slow Virus Diseases Immune System Diseases |
Therapeutic Uses Lentivirus Infections Infection Antiviral Agents Pharmacologic Actions |